Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H R Roberts

Showing results (131-140 of 182) with videos related to

Pageof 19
Sort By:
British Journal of Haematology|March 1, 1980
Characterization of a variant prothrombin in a patient congenitally deficient in factors II, VII, IX and XC A Johnson, K S Chung, K M McGrath, et al.
Thrombosis Research|February 1, 1988
Influence of divalent and monovalent cations on some active site properties of human factor XaD T Manly, G L Featherstone, J W Jenzano, et al.
Blood|January 15, 1992
Role of gamma-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activationR Rawala-Sheikh, S S Ahmad, D M Monroe, et al.
Archives of Biochemistry and Biophysics|May 1, 1985
Activation of normal and abnormal human factor IX with trypsinD M Monroe, C M Noyes, D L Straight, et al.
Archives of Biochemistry and Biophysics|September 1, 1987
Homo- and heterodimer formation with prothrombin and prothrombin fragment 1 in the presence of calcium ionsR C Tarvers, H R Roberts, D L Straight, et al.
Annals of Internal Medicine|June 1, 1977
Liver biopsy in hemophilia AH R Lesesne, J E Morgan, P M Blatt, et al.
The Journal of Clinical Investigation|June 1, 1984
Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitorsH E Fuchs, H G Trapp, M J Griffith, et al.
Instructional Course Lectures|January 1, 1983
The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophiliaC W McMillan, W B Greene, P M Blatt, et al.
Blood|February 15, 1989
Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptideM N Huang, C K Kasper, H R Roberts, et al.
JAMA|December 13, 1976
Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activitiesP M Blatt, K M Brinkhous, H R Culp, et al.
Pageof 19

Showing results (131-140 of 182) with videos related to

Sort By:
Pageof 19
British Journal of Haematology|March 1, 1980
Characterization of a variant prothrombin in a patient congenitally deficient in factors II, VII, IX and XC A Johnson, K S Chung, K M McGrath, et al.
Thrombosis Research|February 1, 1988
Influence of divalent and monovalent cations on some active site properties of human factor XaD T Manly, G L Featherstone, J W Jenzano, et al.
Blood|January 15, 1992
Role of gamma-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activationR Rawala-Sheikh, S S Ahmad, D M Monroe, et al.
Archives of Biochemistry and Biophysics|May 1, 1985
Activation of normal and abnormal human factor IX with trypsinD M Monroe, C M Noyes, D L Straight, et al.
Archives of Biochemistry and Biophysics|September 1, 1987
Homo- and heterodimer formation with prothrombin and prothrombin fragment 1 in the presence of calcium ionsR C Tarvers, H R Roberts, D L Straight, et al.
Annals of Internal Medicine|June 1, 1977
Liver biopsy in hemophilia AH R Lesesne, J E Morgan, P M Blatt, et al.
The Journal of Clinical Investigation|June 1, 1984
Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitorsH E Fuchs, H G Trapp, M J Griffith, et al.
Instructional Course Lectures|January 1, 1983
The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophiliaC W McMillan, W B Greene, P M Blatt, et al.
Blood|February 15, 1989
Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptideM N Huang, C K Kasper, H R Roberts, et al.
JAMA|December 13, 1976
Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activitiesP M Blatt, K M Brinkhous, H R Culp, et al.
Pageof 19